For supply chain security, ‘don’t live in the moment’ - CPHI Frankfurt preview
CPHI caught up with Jim Fries to discuss sustainable supply chains ahead of his CPHI Frankfurt panel discussion
At the core of the pharmaceutical industry is the mission to provide patients with safe, high-quality drugs when they need them. To do this, pharma companies must ensure the timely delivery of their drugs to a potentially global customer base, which requires secure supply chains and a sustainable approach to business.
This will be the subject of the presentation Sustainability, Quality and Supply Chain Integrity: A New View at CPHI Frankfurt this year. In this session, CEO of the nonprofit international consortium Rx-360, Jim Fries will discuss the intersection of sustainability, quality, and supply chain integrity in the post-pandemic era and explore how best practices in one sector can lead to positive changes in the others.
Jim’s session will take place on November 2 – Register for CPHI Frankfurt now.
Jim Fries, Chief Executive Officer, Rx-360
You will be presenting the session Sustainability, Quality and Supply Chain Integrity at CPHI Frankfurt. What can attendees expect to gain from this session?
They will gain a great understanding of how these areas link together. It will leave them thinking about how they can improve in these areas. Every company and organisation is different, my goal is to get them thinking with value points and queries.
The pandemic shone a light on issues in the supply chain and prompted a mass re-evaluation of how to prevent shortages. What advice can you give for promoting supply chain resilience?
Have multiple suppliers and always think ahead. Don’t live in the moment
Why are you attending CPHI Frankfurt this year?
Great opportunity to interact with international colleagues and support the mission of Rx-360 as an international consortium.
We have a packed agenda of content and networking opportunities at this year’s event. What are you most looking forward to?
To be honest, the networking opportunities.
CPHI’s new brand line is ‘At the heart of Pharma’. What does that mean to you?
Understanding what is going on at the root level. Dive deep!
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance